Funding the elimination of viral hepatitis: Donors needed

October 31, 2017

Chronic hepatitis B and C are life-threatening infectious diseases that cause serious liver damage, cancer, and premature death. More than 300 million people are infected with hepatitis B or hepatitis C1 and are at risk of developing escalating health problems. These infectious diseases cause 1·3 million deaths every year1 and are responsible for more than half of all new cases of liver cancer and one in every 12 cancer deaths.2 Whereas the burden of other major infectious diseases such as HIV, tuberculosis, and malaria is decreasing as a result of consistent large-scale global investment, viral hepatitis has been neglected, resulting in ever increasing numbers of people dying from hepatitis B and C.3 Despite the size of the challenge and the years of inaction, in 2016 WHO member states signed up to the goal of eliminating hepatitis B and C as a public health threat by 2030, now just 13 years away. This critical target was agreed because well evidenced solutions for the prevention and treatment of hepatitis B and C exist. Vaccination provides highly effective protection against hepatitis B,1 safe blood and infection control should be the basis of any health system, and harm reduction works. Existing treatment can effectively manage hepatitis B and prevent liver cancer, and new treatments can cure hepatitis C in nearly all patients.4

However, efforts to address viral hepatitis are only just beginning. Few countries have established national plans that make treatment and prevention available for all patients. A lack of national and international investments in viral hepatitis programmes, especially in low-income and middle-income countries, mean that even fewer countries have a national plan that is properly funded. As a result, the vast majority of patients remain undiagnosed--91% of those with hepatitis B and 80% of those with hepatitis C--and only 1% are able to access treatment.1 Even the birth dose hepatitis B vaccine, which can cost less than US$0·20, is not still used in many countries in Africa and the eastern Mediterranean region.1 Part of the problem is that hepatitis B and C are silent epidemics with few obvious symptoms for many years and often hit children and marginalised populations the hardest. Hepatitis B continues to spread unnoticed from mother to child at birth, putting infants at high risk: 80-90% of babies infected with hepatitis B will develop chronic disease and one in four will die of liver-related causes during adulthood.5 Additionally, in low-income and middle-income countries, millions of people have been and continue to be infected, inadvertently and unnoticed, in health-care settings via the use of unsterilised equipment and unscreened blood transfusions.1 People living with HIV are also hard-hit by hepatitis B6 and hepatitis C,7 as are other stigmatised or marginalised groups with poor access to care, such as people who inject drugs, migrants, and indigenous populations.1 The commitment to eliminate hepatitis B and hepatitis C by 2030 matters because it offers the opportunity to prevent approximately 36 million infections and save 10 million lives.8,9

Furthermore, as well as delivering on Sustainable Development Goal (SDG) 3.3 it offers broader progress towards other SDGs, particularly targets to end poverty, ensure good health and wellbeing, and reduce inequalities. Improving access to prevention and treatment services can help protect patients against catastrophic health-care costs and productivity losses. At the same time, many countries will realise cost savings from the elimination of hepatitis B and C. Elimination would help ensure healthy futures for children; protect, empower and reduce stigma among marginalised populations; and support and protect commitments to HIV-positive populations. In an era where the emphasis is more on strengthening health systems than on vertical programmes, viral hepatitis elimination will require many interventions that are crucial for health system strength.

Enhanced infection control services, including injection and blood safety and vaccination for health workers, will improve quality standards in health systems and reduce transmission of health-care-acquired illnesses for both patients and providers. Improved hepatitis B immunisation can help increase coverage of other childhood vaccinations and ensure that newborn babies receive appropriate postnatal care. Prevention of mother-to-child hepatitis B transmission can improve access to perinatal care, ensure healthy pregnancies, and promote institutional deliveries. Harm reduction efforts will help prevent the spread of blood-borne viruses such as HIV and syphilis.

Given the immensity of the task of eliminating hepatitis B and C--diagnosing more than 300 million people stands out as a particular challenge--donors are going to be essential. Domestic funding is unlikely to be able to deliver the results in the 13 years that remain till 2030. None of the big global donors shows any sign of committing to viral hepatitis. However, they are beginning to look at HIV/hepatitis C co-infection and both UNITAID and the UK's Department for International Development (DFID) are supporting market-shaping programmes for hepatitis C. Continued advocacy with donors is needed to support prevention interventions, which almost all positively affect health systems as a whole, and we recommend that donors provide GAVI with the financing required to fund the hepatitis B birth dose. Donors are needed to lay the groundwork for elimination in low-income and middle-income countries by supporting research and policy efforts to develop national hepatitis plans; providing financing and funding for the scale-up of cost-effective interventions; and supporting product and procurement investments to drive down drug and diagnostic prices and bring new technologies to market.

Hepatitis B and C can be eliminated but, given that in most countries the work is only just starting, there is not a moment to lose.

World Hepatitis Alliance

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to